NATCO Announces Launch of the First Generic Version of Revlimid, in the U.S. market

Written by MD Bureau Published On 2022-03-08T14:50:29+05:30 | Updated On 9 Nov 2022 3:47 PM IST

NATCO Announces Launch of the First Generic Version of Revlimid, in the U.S. market

NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene.

New Delhi: NATCO Pharma Limited, NATCO Pharma Limited, along with its marketing partner Arrow International Ltd (an affiliate of Teva Pharmaceutical Industries Ltd), are pleased to announce launch of the first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the U.S. market.

The above strengths of lenalidomide capsules are prescribed in adults for the treatment of (1) multiple myeloma in combination with the medicine dexamethasone (2) certain myelodysplastic syndromes and (3) mantle cell lymphoma following specific prior treatment.

NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).

Natco Pharma Limited was incorporated in Hyderabad in the year 1981. With a modest beginning of operations as a single unit with 20 employees, Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.

Natco family currently consists of around 5000 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. Natco is well recognized for its innovation in Pharmaceutical R&D.

Read Also - Zydus gets DCGI nod for Oxemia

nactoTevalenalidomideCelgeneRevlimid

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.